Patients with advanced cancers refractory to conventional therapy are often enrolled in phase I clinical trials evaluating novel therapeutic agents either alone or in combination with standard chemotherapy. Phase I trials are designed primarily to determine the recommended phase II dose for further testing and to evaluate the clinical tolerability and toxicity of the compounds under investigation. Determination of the optimal dose for conventional cytotoxics is generally based on the assumption that both clinical benefit and toxicity of these agents increases with increasing dose (1, 2) . In these phase I trials, increasing doses are evaluated up to the maximum tolerated dose (MTD), defined as the highest dose that can be administered with acceptable toxicity. This assumption that there is a dose-response relationship has been extrapolated from in vitro data and in vivo models showing that higher exposure to a drug generally increases tumor kill (2) (3) (4) . These findings are expected, considering that conventional cytotoxic agents such as DNA-or tubulin-damaging chemotherapies would affect the faster-dividing malignant cells more than normal cells and that higher doses would induce a greater cell kill through kinetic mechanisms (5, 6) . With rare exception (eg, monoclonal antibodies), the paradigm of driving drug dose escalation to the MTD has been a rule, not only for many years of drug development of cytotoxic agents, but also more recently in the development of small molecule molecularly targeted agents (MTAs).
With our escalating understanding of molecular signal transduction pathways, novel therapeutic agents are increasingly designed to inhibit specific tumor-driven pathways, with the hope that these agents will be more tumor specific and avoid excess toxicity (7) . As a result, many MTAs are now being studied in phase I clinical trials. However, determination of the optimal dose of MTAs for subsequent clinical studies has been controversial, with arguments both for and against the approach of dosing these agents according to their observed MTD (2, (7) (8) (9) (10) . Treatment with MTAs is often associated with organ-specific toxicities, as compared with the antiproliferative toxicities of conventional cytotoxics (4, 11, 12) . Because MTAs often display a differing spectrum of toxicity compared with conventional chemotherapy, use of the traditional primary endpoint of toxicity to determine the recommended phase II dose has been questioned. Instead, the measurement of molecular biomarkers has been proposed as a more appropriate way to indicate clinically effective target inhibition and/or downstream effect while keeping toxicity to a minimum (8) . Instead of designing phase I studies to determine the MTD, it has been argued that it is more biologically, clinically, and economically appropriate to dose according to the minimal effective dose or optimum biologic dose, based on outcomes from biomarker studies (8, 13, 14) . However, it has been argued that the "one-dose-fits-all" minimal effective dose or optimum biologic dose approach may not be appropriate for all patients and may miss certain populations that would benefit from treatment at the MTD (7, 15) . Data from two phase III studies examining the efficacy of the MTA imatinib, conducted in patients with advanced gastrointestinal stromal tumors, indicated that subgroups of patients exist that benefit from therapy with MTAs at the MTD compared with a lower dose (7, (15) (16) (17) . Because of a lack of better alternative strategies and too many uncertainties regarding the use of biomarkers for optimal dose selection, the standard today is to dose MTAs according to their MTDs.
In 2009, Postel-Vinay and colleagues reported the results of a retrospective investigation into whether clinical benefit observed in phase I trials of MTAs was dependent on administered dose (4). Although phase I trials are not typically designed to evaluate clinical benefit, tumor response, or overall survival (OS), response is often a key secondary objective and is usually included in the discussion at the time of patient enrollment (18) . Postel-Vinay and colleagues retrospectively analyzed the outcomes of patients enrolled in phase I trials at the Drug Development Unit, Royal Marsden Hospital, United Kingdom, treated with monotherapy MTAs over an 18-month period from January 2005 to June 2006. Three patient cohorts were identified according to the dose received as a percentage of the final identified MTD (A = 0%-33%, B = 34%-65%, C = >66%). Potential efficacy or clinical benefit was assessed as the nonprogression rate, defined as complete response (CR), partial response (PR), or stable disease for at least 3 months by response evaluation criteria in solid tumors. A total of 135 patients from 15 eligible trials were analyzed. Cohorts A, B, and C included 28 (21%), 22 (16%), and 85 (63%) patients, respectively. The nonprogression rate at 3 and 6 months was 21% and 11% for cohort A, 50% and 27% for cohort B, and 31% and 14% for cohort C, respectively. Median duration of nonprogression (17 weeks; 95% confidence interval [CI] = 13 to 22) was not related to percentage of MTD level (P = .90). The authors concluded that, in phase I trials of MTAs, the potential for clinical benefit is not confined to patients treated at doses close to the MTD (4) .
Similarly, in 2010, Jain and colleagues reported the results of a study examining clinical responses across dose levels in 24 clinical trials of MTAs conducted at the MD Anderson Cancer Center, Houston, Texas, between October 2004 and June 2008 (6) . Six hundred and eighty-three patients were evaluated for response rate, time-to-treatment failure, progression-free survival, OS, and toxicity, with 97.7% receiving MTAs either as monotherapy or in combination. Four hundred patients were treated with monotherapy MTAs, whereas 283 received a combination of MTAs. These patients were grouped into three categories according to the dose level received relative to the MTD: low (≤25% MTD), medium (25%-75% MTD), and high (≥75% MTD). After analysis, the low-dose group was found to fare equivalently to the other dose groups in terms of response rate, progression-free survival, OS, and toxicity and even had a modestly more favorable outcome in timeto-treatment failure at 3 months (32.9% vs 25.2%, P = .08). The authors also concluded that, in phase I trials of MTAs, there was no discernible benefit to being treated at the MTD compared with lower doses (6) .
Both the Postel-Vinay and Jain reports examined a relatively small number of patients treated at a single institution with multiple studies executed over a fairly short time period. Given these features, a small change in clinical benefit due to increasing dose would be difficult to observe. The purpose of the present study was to examine the relationship between dose and clinical benefit in a large number of phase I studies of MTAs executed over a 10-year time span, involving a large number of patients treated at multiple institutions across North America.
Methods

Eligibility Criteria
The intended analysis population consisted of nonpediatric (aged ≥18 years) patients enrolled from May 2000 to December 2009 in phase I oncology trials of MTAs sponsored by the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP). All trials included regular protocol-specified patient follow-up and clinical response evaluations. Trials evaluating solid tumors and hematologic malignancies were included in the meta-analysis and met all of the following criteria: 1) trials were evaluating an MTA, with an MTA being defined as any agent with any extra-or intracellular target different from those associated with conventional chemotherapy (DNA, tubulin, or cell division machinery) (4); 2) trials were evaluating an MTA in monotherapy (combinations with conventional and/or investigational chemotherapies, other MTAs, or radiotherapy were excluded); 3) trials were using drugs with a described and/or defined MTD or at least one patient who had received treatment at the maximum planned dose; and 4) response data had to be complete. All administered dose levels (levels 1 through 6) were defined as a percent of the final identified MTD or maximum planned dose for the drug (does level 1 = <20%; dose level 2 = 21%-40%; dose level 3 = 41%-60%; dose level 4 = 61%-80%; dose level 5 = 81%-100%; dose level 6 = >100%). Dose levels were defined a priori at regular 20% intervals to avoid data-driven cutpoints. Response to treatment reported for each MTA study was categorized as CR, PR, less-than-partial response, or stable disease, according to guidelines of the World Health Organization (19) and the response evaluation criteria in solid tumors (20) . For this analysis, less-than-partial response (according to the World Health Organization criteria) and stable disease were combined into one category.
Information Source
CTEP oversees clinical trials of investigational anticancer agents at various clinical institutions across North America. The program receives comprehensive trial data at regular intervals from investigators and actively monitors all trials through routine data submission and periodic audits. Data from phase I trials sponsored by CTEP are monitored by the Clinical Trials Monitoring System. The Clinical Trials Monitoring System has been managed by Theradex Systems, Inc. since 1979. It is a database of electronically submitted case-report forms for "first in human" clinical trials as well as trials of combinations of investigational new drugs and US Food and Drug Administration-approved drugs. Extensive data are submitted every two weeks for quality control and are maintained in an Oracle database. Each institution participating in a CTEPsponsored clinical trial is audited for quality assurance three times a year.
Statistical analysis
The relationship of dose to OS was analyzed using a Cox proportional hazards model (21) . This model was used to test for statistical significance of covariates because the proportional hazards model is valid for hypothesis testing even when the assumption of proportionality is violated. For patients who received a drug at more than one dose level, the dose level that was given most often was used in the analysis. An analysis with best response at six to eight weeks or 12 weeks was performed. For 56% of the patients, only response at six to eight weeks was available because the majority of these patients came off study for disease progression and toxicity. A positive response was defined as either a CR or PR. The relationship between dose and best response was analyzed using a logistic regression model. The dose level in this analysis is the dose given at the time of the best response.
In both the Cox and logistic regression models, covariates that may influence the endpoint (OS or response) were accounted for (modeled) in either of two ways. For the first model (termed the study model), a variable to indicate different studies was included in the model along with dose, as is standard practice in meta-analyses. This model controls for known and unknown differences that exist between the studies. For the second model (termed the demographic model), demographic variables that were thought to be prognostic of the endpoint were included in the model along with dose. In the demographic model, study was not included because the demographic covariates would be highly correlated with a study covariate.
The demographic variables that were considered were sex, age (per five-year increase), albumin, white blood cell count (per fiveunit increase), performance status, number of prior chemotherapy regimens, time from diagnosis to start of treatment, tumor type, creatinine level, lactate dehydrogenase, hemoglobin, and platelets. After examining the initial model with all demographic variables included, covariates that were not statistically significant at the .15 level (two-sided) were not considered to be strongly related to response and were dropped from the model. Tumor type was included as an indicator variable, and the likelihood ratio test was used to simultaneously test whether there was a statistically significant difference in the relationship of the endpoints to tumor types. Dose was treated as an indicator variable so that the relationship between the drugs and the endpoint did not have to be of the same magnitude across dose levels and so that a monotonic relationship between dose level and endpoint was not imposed. Including dose as a continuous variable could be more powerful if the correct relationship was specified (ie, linear, in that the same increase in response rate occurred for each dose level); however, if the specified relationship were incorrect, a dose-response relationship could be missed. Dose levels associated with similar effect sizes were collapsed into one dose level. After the analysis was performed on all the data, the final models (both the study model and the demographic model) were rerun with the data separated by solid and hematologic malignancies. Kaplan-Meier curves were estimated to plot OS by time. The curves were estimated separately for hematologic and solid tumor malignancies and also for low doses (≤60% of MTD) and high doses (>60% of MTD). In both proportional hazard models and logistical regression models, two-sided statistical testing was used.
Results
Trial Characteristics
Data from 83 clinical trials involving a total of 2873 patients treated with an MTA through the National Cancer Institute's CTEP program between May 2000 and December 2009 were available. Of these, 28 trials involving 965 patients were excluded according to our earlier-defined eligibility criteria as follows: 24 trials with 750 patients were excluded because of the use of multiple MTAs (criterion 2), one trial with 32 patients was excluded because of the lack of a defined MTD or maximum planned dose (criterion 3), and three trials with 183 patients were excluded because of incomplete response data (criterion 4). A total of 55 studies conducted by more than 25 lead institutions and involving 1908 patients were deemed eligible and included in our final analyses. The general mechanisms of action for the agents evaluated in these trials are listed in Table 1 . Table 2 gives the proportion of patients in each dose level for the categorical demographic variables and the proportion of responses for all patients, solid tumors, and hematologic tumors. Patients are grouped by dose levels 1, 2, and 3 (low) and dose levels 4, 5, and 6 (high). Distribution across the different sex, performance status, prior therapy, and tumor type categories is similar for the low-and highdose levels. The observed proportion of responses is higher for the hematologic tumors. The mean and standard deviations of age, creatinine, albumin, and hemoglobin for the low-and high-dose levels are also included in Table 2 . For each variable, the means and standard deviations are similar across dose levels. Values for the continuous demographic variables for lactate dehydrogenase, white blood cell count, and platelets have skewed distributions; for these variables, medians and the median absolute deviations are given for each dose level in Table 2 . Again, the medians and median absolute deviations are similar across dose-level categories. Although an abundance of censored data was included in our meta-analysis (50% were censored by 2.3 months), 93 patients had follow up of more than 1.5 years. Table 3 shows that for the analysis combining hematologic and solid tumors, OS increases as dose level increases. This relationship exists for the study model, which controls for differences in studies by including study as a covariate, and for the demographic model, which controls for differences by including prognostic variables. The grouping of the dose variables was slightly different for the two models. In the study model, doses 4, 5, and 6 were combined into a high dose. The hazard ratios (HRs) comparing dose 2 to dose 1, dose 3 to dose 1, and high dose to dose 1 decreased as dose increased (HRs = 0.56, 0.47, and 0.37 respectively), with the comparison of dose 3 to dose 1 and high to dose 1 statistically significantly different from one (P = .049 and P = .008, respectively). In the demographic model, doses 1, 2 and 3 were collapsed (low dose) and doses 4, Table 2 . Patient characteristics grouped by dose levels 1 to 3 (low dose) and dose levels 4 to 6 (high dose)* 5, and 6 were collapsed (high dose) because the estimates of the hazard ratios were similar for grouped dose levels. The hazard ratio comparing the high-dose group with the low-dose group is 0.59 (P = .002). The only demographic variables that were included in the final model were age, albumin, and white blood cell count. For solid tumors, the survival results mirrored the overall results, with a statistically significant increase in OS as dose increased. In large part, the reason the solid tumor results followed the pattern of the overall results is that the solid tumor group contained 62% (95 of 152) of the events of the total data set. For hematologic tumors, OS results did not follow the same pattern; OS did not statistically significantly increase as dose increased. Figure 1 shows the OS curve estimates by tumor type separated by low-and high-dose levels. Table 4 shows that as dose increases from dose levels 1, 2, and 3 to dose levels 4, 5, and 6, the odds of a response increase in a statistically significant manner. This relationship is strongest in the demographic model (P = .01; model includes prognostic variables) and is close to statistically significant for the study model (P = .10; model includes study as a covariate). The demographic variables included in the final model were performance status, number of prior chemotherapy regimens, and tumor type. The solid tumor response results again mirrored the overall results, with a trend for the odds of a response increasing as dose increased from low to high (P = .08 for the study model, P = .08 for the demographic model). For hematologic tumors, the odds ratios were in the same * A hazard ratio less than 1.0 indicates increased survival for the first variable over the second. † Dose levels grouped as follows: dose level 1 = <20%; dose level 2 = 21%-40%; dose level 3 = 41%-60%; dose level 4 = 61%-80%; dose level 5 = 81%-100%; dose level 6 = >100%. ‡ The samples are smaller due to missing covariate information. Figure 1 . Kaplan-Meier curves of high dose (dose levels 4, 5 and 6) vs low dose (dose levels 1, 2, and 3) for solid tumors and hematologic (Heme) tumors. The numbers at the bottom of the figure show the number of patients at risk for each time point. All administered dose levels (levels 1-6) were defined as a percent of the final identified maximum tolerated dose or maximum planned dose for the drug. Heme Low and Solid Low = dose level 1 (<20%), dose level 2 (21%-40%), and dose level 3 (41%-60%); Hem High and Solid High = dose level 4 (61%-80%), dose level 5 (81%-100%), and dose level 6 (>100%). was used to simultaneously test whether there was a statistically significant difference in response rates among tumor types. The odds ratio is not presented because there is not one odds ratio. ‡ All tumor types other than hematologic.
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JNCI | Articles 1865 jnci.oxfordjournals.org direction as the solid tumor odds ratios but were not statistically significantly different from one (P = .50 for the study model, P = .11 for the demographic model). Table 2 shows that the observed overall response rate is higher for hematologic tumors (response rate = 0.14) than for solid tumors (response rate = 0.07).
Discussion
In our meta-analysis, patients treated in the context of phase I trials with MTAs derived reasonable clinical benefit. The probability of response and OS increased with higher doses even after controlling for covariates associated with response. Contrary to other singleinstitution data, our results suggest that potential clinical benefit in terms of overall response and OS correlates in a statistically significant manner with administered dose level, with increasing benefit for patients treated at doses at or near the MTD.
In their published papers, Postel-Vinay and colleagues and Jain and colleagues attempted to answer a critical question relative to phase I trials of MTAs: do response and survival increase as dose increases? Reporting the results of meta-analyses using clinical trials that recruited patients at their respective institutions, both groups concluded that dose may not matter and that similar proportions of responses are expected across all dose levels. In contrast, our analysis of a greater number of agents and patients recruited at multiple institutions across North America demonstrated a doseresponse relationship with MTAs in a phase I setting; specifically, higher proportions of responses were observed at higher doses. There may be several reasons for the different conclusions.
Our analysis was based on a much larger dataset than either of the previous analyses. We reviewed data from a total of 55 clinical trials and 1908 patients. Jain's meta-analysis included 24 phase I trials with 683 patients (only 400 patients evaluating MTAs as monotherapy) and Postel-Vinay included 15 trials with 135 patients. This difference is important to note because, in the phase I setting, many drugs are studied and few actually exhibit antitumor activity. As an example, inclusion of more members of drug classes such as angiogenesis inhibitors, which typically exhibit little monotherapy antitumor efficacy, could skew the results of a smaller meta-analysis and result in a different conclusion than was reached here. Any meta-analysis including all studies without regard to agent activity will underestimate the overall dose response relationship because agents with no activity will dilute it. A negative result does not necessarily mean a dose-response relationship does not exist. The signal or dose-response relationship may be small and not detectable statistically because of the small data sets, or it could mean the studies did not treat patients over a sufficient dose range from subtherapeutic to therapeutic doses. Therefore, differences in the datasets for each report need to be described to fully understand the differences in conclusions.
Postel-Vinay and Jain only included studies from single centers. Single institutional studies may not be representative of the general phase I oncology patient population because of many factors. Among these are selection bias (including tumor type, prior therapy, performance status) and patient referral patterns unique to a particular institution. Additionally, clinical trials conducted by a tumor-specific service at a single institution may result in the accrual of patients with a limited tumor type that may not necessarily hold therapeutic relevance to the agent under study.
Another difference is that the inclusion periods of the studies chosen for the Postel-Vinay and Jain analyses were relatively short compared with the nearly decade-long inclusion criteria for our analysis: 1.5 years for Postel-Vinay and four years for Jain). This short timeframe for recruitment of patients only allowed for evaluation of a small subset of MTAs that happened to be in development at a specific and limited period of time, and the follow-up may have been too short to fully detect survival differences. If, in this small subset of drugs in development during this limited time, agents were studied that manifested limited activity, then the outcomes would be similar regardless of the dose, and these negative trials could have heavily skewed the outcome. Additionally, to predict differences in survival, the dataset must contain enough events (deaths). If patients are not followed long enough so that deaths are observed, a differential in survival cannot be defined. In some phase I populations, a 1.5-year survival may be sufficient, especially if there are no responders. However, if responders exist, a short interval may not capture a large enough number of events to define a differential. As stated earlier, an abundance of censored data was included in our meta-analysis (50% were censored by 2.3 months), and 93 patients had follow up for more than 1.5 years.
Our study included both solid and hematologic tumor patients. We found that there was a strong relationship between dose and outcomes in solid tumor patients but not in hematologic patients. However, the solid tumor patients composed 73% of the data, so there was more power to detect a difference in this group. It is unclear whether we would have found an effect had more patients been present in the hematologic group because the hazard ratios and odds ratios appeared to be in the same direction as the solid tumor group, but less strong. Aside from lack of power, there are other possibilities for why we did not detect a stronger doseresponse relationship in hematologic tumors. For example, it is possible that the doses of drugs targeting hematologic tumors were not explored at a wide enough range, so that some patients responded and some patients did not. Another possibility is that hematologic tumors may be more sensitive than solid tumors or the drugs targeting the tumors may be more effective, so more of the dose level studies for an active agent were active dose levels. It is not clear whether the previously reported Postel-Vinay and Jain investigations included substantial proportions of patients with hematologic tumors. If they did, another reason the previous investigations may not have observed a dose-response relationship could be the resultant dilution in effect.
In our meta-analysis, many of the evaluated agents came from pharmaceutical sponsors that were also being developed in collaboration with cooperative research and development agreements with CTEP. As a result, several of these agents had already undergone preliminary evaluation with encouraging results. The CTEP trials often evaluated alternative phase I dosing and schedules, a variety of disease types, special patient populations, and similar phase I schedules with alternative endpoints. As a result, the drug candidates may have, overall, been unique relative to the phase I drugs under investigation in both the Postel-Vinay and Jain studies and had a higher probability of demonstrating antitumor activity and subsequent dose-response effect.
A limitation of all three meta-analysis described herein is that patients were not preselected based on molecular characterization of the tumor. Preselection may lead to a greater probability of response across all dose levels. However, it is unknown if a higher dose in a molecularly characterized patient population will or will not translate into either a more durable response or greater survival benefit. These types of trials are desperately needed, not only to define the true worth of personalized medicine but also to guide the use of MTAs for future use. As preselection and novel phase I trial designs become standard, it is important to keep in mind that metaanalyses like the ones described within the context of this paper may no longer be relevant due to the differences in patient selection.
The results showing that OS and response both increase as dose increases is important to realize in the context of current recruitment strategies to phase I clinical trials of MTAs, especially when patients are not preselected by target. When patients are consented to these clinical trials, it may not be appropriate to state that the dose to which a patient is being recruited does not matter. As the biology of cancer is better understood and well-defined targets become known, additional analyses in the context of defined drugg able targets must be performed to determine whether a personalized medicine approach will alter the outcome of dose cohort recruitment for future phase I studies.
